Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy

Authors

  • M. Blondon,

    Corresponding author
    1. Department of Medicine, Geneva University Hospitals, Geneva, Switzerland
    • Department of Epidemiology, University of Washington, Seattle, WA, USA
    Search for more papers by this author
  • K. L. Wiggins,

    1. Department of Medicine, University of Washington, Seattle, WA, USA
    Search for more papers by this author
  • L. B. Harrington,

    1. Department of Epidemiology, University of Washington, Seattle, WA, USA
    Search for more papers by this author
  • B. M. Psaty,

    1. Department of Epidemiology, University of Washington, Seattle, WA, USA
    2. Department of Medicine, University of Washington, Seattle, WA, USA
    3. Department of Health Services, University of Washington, Seattle, WA, USA
    4. Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA
    Search for more papers by this author
  • N. L. Smith

    1. Department of Epidemiology, University of Washington, Seattle, WA, USA
    2. Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA
    3. Department of Veterans Affairs Office of Research and Development, Seattle Epidemiologic Research and Information Center, Seattle, WA, USA
    Search for more papers by this author

  • Disclaimers: part of this work was presented as a poster at the 5th International Symposium on Women's Health Issues in Thrombosis and Haemostasis (Vienna, February 2013).
  • Manuscript handled by: F. R. Rosendaal
  • Final decision: F. R. Rosendaal, 23 May 2013

Correspondence: Marc Blondon, University of Washington, Cardiovascular Health Research Unit, Metropolitan Park East Tower, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA.

Tel.: +1 206 287 2777; fax: +1 206 287 2662.

E-mail: blondm@uw.edu, marc.blondon@hcuge.ch

Ancillary